

Eric D. Donnenfeld, M.D. of Ophthalmic Consultants of Long Island Performs First iStent® case in NY Tri-State Area

Westbury, NY (August 1, 2012) – On Tuesday, August 7, Dr. Eric D. Donnenfeld, founding partner of Ophthalmic Consultants of Long Island (OCLI), will be performing the first microinvasive glaucoma surgery using the iStent® in the New York Tri-State area. The Glaukos® iStent® Trabecular Micro-Bypass stent was recently approved by the FDA and reduces intraocular pressure (IOP) in patients with mild to moderate glaucoma and cataracts.

“Traditionally, glaucoma is controlled with medication but the iStent device offers a possible alternative solution to reduce a patient’s dependency on glaucoma medication following cataract surgery,” said Dr. Donnenfeld. Two years ago, Dr. Donnenfeld was the only principal investigator in the New York area running this trial, one of the first studies of its kind in the U.S. Dr. Donnenfeld has also been involved with studies of the iStent outside of the U.S and has implanted over 100 devices.

At less than .3mm long, the iStent is the smallest medical device ever approved by the FDA and the smallest stent known to be implanted in the human body. It is placed in the eye during cataract surgery and is so small that patients won’t be able to see or feel it after the procedure is over. The stent is designed to reduce IOP in glaucoma patients following cataract surgery and may reduce or eliminate the need for eye drops in some patients. The iStent is designed to reduce the challenges and risks of traditional glaucoma management. According to Dr. Donnenfeld, “We now have the technology to remove cataracts and reduce dependency on glasses and glaucoma medications.

Dr. Donnenfeld practices in OCLI’s Rockville Centre and Lynbrook offices. He has been a leader in ophthalmology for more than two decades. Dr. Donnenfeld was one of the original investigators of the excimer laser and has performed tens of thousands of laser vision corrective surgical procedures. Dr. Donnenfeld has served as president of many professional societies including the Nassau Surgical Society, cornea section of ASCRS, the Ophthalmology Division of the Nassau Academy of Medicine, and the International Ocular Microbiology and Immunology Group. He is on the executive board of ASCRS and will be president in 2013 and is the chief editor of *Cataract and Refractive Surgery Today*. He has written over 170 papers on cornea, external disease, cataract and refractive surgery, and 20 book chapters and books. He is on the editorial board of nine journals and has participated in over 40 FDA studies. He is a Fellow of

the American Academy of Ophthalmology and has received its Honor Award, Senior Honor Award and Secretariat Award.